505 related articles for article (PubMed ID: 30803900)
1. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
Romanet T; Bedouch P; Zaoui P
Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
3. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
[TBL] [Abstract][Full Text] [Related]
4. [Clinical experience with ferric carboxymaltose in non-dialysis chronic kidney disease].
Minutolo R; Liberti ME; Garofalo C; Pacilio M; Sagliocchi A; Sguazzo A; Scarpati L; Sagliocca A; Santangelo S; Provenzano M; Savino M; Conte G; De Nicola L
G Ital Nefrol; 2015; 32(5):. PubMed ID: 26480261
[TBL] [Abstract][Full Text] [Related]
5. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.
Rognoni C; Ortalda V; Biasi C; Gambaro G
Adv Ther; 2019 Nov; 36(11):3253-3264. PubMed ID: 31489572
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
8. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
[TBL] [Abstract][Full Text] [Related]
9. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
Macdougall IC; Bock A; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Cushway T; Roger SD;
Nephrol Dial Transplant; 2014 Apr; 29(4):843-50. PubMed ID: 24170814
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
11. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
12. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.
Toledano A; Luporsi E; Morere JF; Scotté F; Laribi K; Barrière J; Huot-Marchand P; Duvillié L; Concas VH; Bugat R
Support Care Cancer; 2016 Jan; 24(1):67-75. PubMed ID: 25921449
[TBL] [Abstract][Full Text] [Related]
14. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
15. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Bansal SS; Cronin M; Meier Y; Larroque S; Roger SD; Macdougall IC
PLoS One; 2016; 11(6):e0157063. PubMed ID: 27276035
[TBL] [Abstract][Full Text] [Related]
16. Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis.
Cirillo L; Somma C; Allinovi M; Bagalà A; Ferro G; Di Marcantonio E; Bellelli S; Dallari LA; Ballo P; Dattolo PC
Sci Rep; 2021 Apr; 11(1):7463. PubMed ID: 33811227
[TBL] [Abstract][Full Text] [Related]
17. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.
Lichtenstein GR; Onken JE
Dig Dis Sci; 2018 Nov; 63(11):3009-3019. PubMed ID: 30056562
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
Covic A; Mircescu G
Nephrol Dial Transplant; 2010 Aug; 25(8):2722-30. PubMed ID: 20190247
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
Diebold M; Kistler AD
BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
[TBL] [Abstract][Full Text] [Related]
20. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
Wilson PD; Hutchings A; Jeans A; Macdougall IC
J Med Econ; 2013; 16(1):108-14. PubMed ID: 22989163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
